Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8647316 | Multiple Sclerosis and Related Disorders | 2018 | 12 Pages |
Abstract
Raltegravir did not have any impact on MS disease activity. This could be due to the choice of antiretroviral agent used in this study, the need for a combination of agents, as used in treating HIV infection, the short treatment period or dosing regimen, or the lack of a role of HERV expression in MS once the disease is established. Borderline significance for the association between EBV shedding and the total number of lesions, probably driven by new lesion development, may indicate EBV shedding as a marker of inflammatory disease activity. In conclusion, interesting correlations between HERV-W markers, EBV shedding and new MRI lesions, independent from treatment effects, were found.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Julian Gold, Monica Marta, Ute C. Meier, Tove Christensen, David Miller, Daniel Altmann, David Holden, Lucia Bianchi, Rocco Adiutori, David MacManus, Tarek Yousry, Klaus Schmierer, Benjamin Turner, Gavin Giovannoni,